表紙
市場調査レポート

AFFiRiS AGの製品パイプライン分析

AFFiRiS AG - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224743
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
AFFiRiS AGの製品パイプライン分析 AFFiRiS AG - Product Pipeline Review - 2016
出版日: 2016年02月24日 ページ情報: 英文 34 Pages
概要

AFFiRiS AGはオーストリアに本社をおくバイオテクノロジー企業です。新たな治療薬を必要とする慢性疾患に対し、合成ワクチン開発を行っています。アルツハイマー、アテローム性動脈硬化症、多系統萎縮症(MSA)、糖尿病などに対し、独自のAFFITOME技術を基盤にペプチドワクチンをカスタマイズした予防薬の開発を行っています。

当レポートでは、AFFiRiS AG における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

AFFiRiS AG の基本情報

  • AFFiRiS AG の概要
  • 主要情報
  • 企業情報

AFFiRiS AG :R&Dの概要

  • 主な治療範囲

AFFiRiS AG :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

AFFiRiS AG :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

AFFiRiS AG :薬剤プロファイル

  • AD-02
  • IMMAD-04
  • ATH-03
  • PD-01
  • PD-03
  • Vaccine for Chronic Kidney Disease
  • Vaccine for Type 2 Diabetes
  • Vaccine to Target Angiotensin II for Cardiovascular Diseases
  • Vaccine to Target PCSK9 for Atherosclerosis
  • Undisclosed Drug-1
  • Undisclosed Drug-2

AFFiRiS AG :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別

AFFiRiS AG :最近のパイプライン情報

AFFiRiS AG :開発が休止されたプロジェクト

AFFiRiS AG :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07949CDB

Summary

Global Markets Direct's, 'AFFiRiS AG - Product Pipeline Review - 2016', provides an overview of the AFFiRiS AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AFFiRiS AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AFFiRiS AG
  • The report provides overview of AFFiRiS AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AFFiRiS AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AFFiRiS AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AFFiRiS AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AFFiRiS AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AFFiRiS AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AFFiRiS AG Snapshot
    • AFFiRiS AG Overview
    • Key Information
    • Key Facts
  • AFFiRiS AG - Research and Development Overview
    • Key Therapeutic Areas
  • AFFiRiS AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AFFiRiS AG - Pipeline Products Glance
    • AFFiRiS AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • AFFiRiS AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • AFFiRiS AG - Drug Profiles
    • ATH-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AD-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATH-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PD-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Allergic Rhinitis and Asthma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Huntington's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target C5a for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target PCSK9 for Hypercholesterolemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AFFiRiS AG - Pipeline Analysis
    • AFFiRiS AG - Pipeline Products by Target
    • AFFiRiS AG - Pipeline Products by Route of Administration
    • AFFiRiS AG - Pipeline Products by Molecule Type
  • AFFiRiS AG - Recent Pipeline Updates
  • AFFiRiS AG - Dormant Projects
  • AFFiRiS AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AFFiRiS AG, Key Information
  • AFFiRiS AG, Key Facts
  • AFFiRiS AG - Pipeline by Indication, 2016
  • AFFiRiS AG - Pipeline by Stage of Development, 2016
  • AFFiRiS AG - Monotherapy Products in Pipeline, 2016
  • AFFiRiS AG - Phase I, 2016
  • AFFiRiS AG - Preclinical, 2016
  • AFFiRiS AG - Pipeline by Target, 2016
  • AFFiRiS AG - Pipeline by Route of Administration, 2016
  • AFFiRiS AG - Pipeline by Molecule Type, 2016
  • AFFiRiS AG - Recent Pipeline Updates, 2016
  • AFFiRiS AG - Dormant Developmental Projects,2016

List of Figures

  • AFFiRiS AG - Pipeline by Indication, 2016
  • AFFiRiS AG - Pipeline by Stage of Development, 2016
  • AFFiRiS AG - Monotherapy Products in Pipeline, 2016
  • AFFiRiS AG - Pipeline by Target, 2016
  • AFFiRiS AG - Pipeline by Molecule Type, 2016
Back to Top